Ribosomal protein L7a pseudogene 23 (RPL7AP23)

RPL7AP23 is a processed pseudogene derived from the ribosomal protein L7a gene, annotated as such in multiple genetic databases[4][5]. Pseudogenes like RPL7AP23 are genomic sequences resembling functional genes but typically lack coding potential due to accumulated mutations, truncations, or absence of regulatory elements, and are not translated into functional proteins[4][5][7]. While the parent gene, ribosomal protein L7a (RPL7A), encodes a component of the 60S ribosomal subunit and participates in protein synthesis, pseudogenes such as RPL7AP23 do not code for active proteins and lack well-defined biological functions. Occasionally, pseudogenes may be transcribed into non-coding RNAs that have subtle regulatory roles in the cell, but for RPL7AP23, no such specific function has been described[4][5]. Pseudogenes are not considered direct therapeutic targets (unlike receptors, enzymes, or ion channels), as they typically do not encode functional proteins or have a defined mechanism of action relevant to drug discovery or clinical intervention[5][7]. There are no known drugs, mechanisms of drug interaction, nor established safety concerns associated with this pseudogene. The entry and its nomenclature are correct according to current genomic annotation standards, and all alternative names point to its processed pseudogene status[4][5][8]. If further information about disease associations, biological function, or therapeutic targeting of pseudogenes emerges, it most likely pertains to RNA-level regulatory mechanisms, not classical small molecule or biological drug targeting. No such evidence exists for RPL7AP23 specifically at this time.

Other names

RPL7A_5_385[4]